Latest News

The newly introduced National Strategy for Vector Surveillance reflects Oman’s commitment to strengthening health security in line with Oman Vision 2040.

The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.

Dr. Melly currently serves as Kenya’s cancer country counterpart lead for the International Atomic Energy Agency and is affiliated with several global oncology bodies, including the Union for International Cancer Control and the Association of American Cancer Institutes.

A defining feature of the ranking methodology is its reliance on globally recognized tools such as Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs).

The Sokoto deployment builds on findings from an extensive randomized controlled implementation study conducted in Nigeria in collaboration with PATH, Jhpiego, the National Primary Health Care Development Agency, and Sydani Group.

As part of the collaboration, GMSC will work directly with M42’s clinical and operational teams to enhance demand forecasting, improve procurement efficiency, and provide greater inventory visibility across facilities.

The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.

Catalyst Pharmaceuticals, listed on Nasdaq in 2006, has evolved into a focused rare disease company with strong commercial momentum.

Neuralink’s clinical programme has recorded notable early milestones, including reports that its first human participant successfully operated a computer and typed using neural signals alone.

The newly introduced National Strategy for Vector Surveillance reflects Oman’s commitment to strengthening health security in line with Oman Vision 2040.